Effects of Yinaojieyu prescription on the kidney deficiency and liver depression of Parkinson's disease and the effect on DA, 5-HT and NE in serum

doi:10.12092/j.issn.1009-2501.2018.04.012

Abstract

Abstract:

AIM: To investigate the clinical efficacy of Yinaojieyu prescription in the treatment of depression of kidney deficiency and liver depression type Parkinson disease, and to evaluate the effects of Yinaojieyu prescription on serum DA, 5-HT and NE. METHODS: Sixty patients with depression of kidney deficiency and liver depression type Parkinson disease were divided into the study group and the control group, 30 cases in each group. The control group was treated with paroxetine tablets. The study group was treated with Yinaojieyu prescription. Hamilton Depression Scale (HAMD) was used to evaluate the depressive state of patients. The Unified Parkinson Disease Rating Scale (UPDRS) was used to assess the condition of Parkinson's disease in the patient. WHO quality of life scale (WHOQOL-BREF) was used to assess the quality of life of patients with made. The levels of serum dopamine (DA), 5-serotonin (5-HT) and norepinephrine (NE) were measured before and after treatment in the two groups. RESULTS: The curative effect of the study group was higher than that of the control group, but the difference was not statistically significant (P>0.05); HAMD score and UPDRS score of the two groups after treatment were significantly decreased, while WHOQOL-BREF scores increased significantly (P<0.05); HAMD score and UPDRS score of the study group after treatment were lower than those of the control group; WHOQOL-BREF score was higher than that of the control group (P<0.05); The levels of DA, NE and 5-HT in two groups after treatment were significantly higher than those before treatment (P<0.05); after treatment, DA, NE, 5-HT of the study group increased as compared with the control group (P<0.05).No significant difference was observed of incidence of adverse reactions between the two groups (P>0.05). CONCLUSION: Yinaojieyu prescription is effective in treating Parkinson's disease with kidney deficiency and liver depression type, and can improve the levels of DA, 5-HT and NE.

Key words: Yinaojieyu prescription, Parkinson's disease, depression, DA, 5-HT, NE

CLC Number:

R965.2

ZHOU Rong, LI Wei, HU Wanhua. Effects of Yinaojieyu prescription on the kidney deficiency and liver depression of Parkinson's disease and the effect on DA, 5-HT and NE in serum[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 434-439.

References

［1］刘娜. 帕金森病患者血尿酸的改变及其与抑郁、焦虑的相关性［J］. 实用临床医药杂志, 2014, 18(15):163.
［2］张海军. 帕罗西汀联合治疗帕金森病合并抑郁和焦虑症状的疗效分析［J］. 现代中西医结合杂志, 2015, 24(6):649-651.
［3］袁清洁, 刘岑, 曹克刚,等. 益肾疏肝法辨治帕金森病与抑郁共病40例临床观察［J］. 现代中医临床, 2014, 21(6):19-22.
［4］中华医学会神经病学分会运动障碍及帕金森病学组. 帕金森病治疗指南［J］. 中华神经科杂志, 2006, 39(6):409-412.
［5］中华医学会神经病学分会神经心理学与行为神经病学组. 帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南［J］. 中华神经科杂志, 2013, 46(1):56-60.
［6］郑筱萸. 中药新药临床研究指导原则［M］. 北京：中国医药科技出版社, 2002:49-52.
［7］Hamilton M. Hamilton depression scale［M］. New York: Group, 2004:126-130.
［8］佚名. 统一帕金森病评定量表［J］. 中华老年医学杂志, 1999, 18(1):61-62.
［9］Nahler MPG. quality of life scale［M］//Dictionary of Pharmaceutical Medicine. Vienna: Springer, 2009:101-128.
［10］郑春叶, 雒晓东, 马丹丹,等. 柴甘解忧汤对帕金森病抑郁大鼠海马神经元及BDNF表达的影响［J］. 广州中医药大学学报, 2016, 33(1):84-87.
［11］宋春艳, 何丽华, 孙洪伟. 颐脑解郁方对冠心病伴抑郁患者的临床疗效观察［J］. 河北医学, 2016, 22(5):836-838.
［12］赵瑞珍, 唐启盛, 田青, 等. 颐脑解郁方对脑出血后抑郁大鼠核磁共振波谱的干预作用［J］. 中国科学:生命科学, 2016, 46(8):959.
［13］Broen MP, Moonen AJ, Kuijf ML, et al. Factor analysis of the hamilton depression rating scale in Parkinson's disease［J］. Parkinsonism Relat Disorders, 2015, 21(2):142-146.
［14］Menon B, Nayar R, Kumar S, et al. Parkinson's disease, depression, and quality-of-Life［J］. Indian J Psychol Med, 2015, 37(2):144.
［15］冼君定, 谭健烽, 万崇华,等. WHOQOL-BREF量表用于精神分裂症和抑郁症的信效度研究［J］. 中华疾病控制杂志, 2015, 19(5):500-503.
［16］Friedman AK, Walsh JJ, Juarez B, et al. Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience［J］. Science, 2014, 344(6181):313-319.
［17］池名, 青雪梅, 潘彦舒,等. 120例抑郁症患者大脑多神经递质变化初探［J］. 中国中药杂志, 2014, 39(8):1516-1524.
［18］Deurwaerdère PD, Ding Y. Antiparkinsonian treatment for depression in Parkinson's disease: Are selective serotonin reuptake inhibitors recommended ［J］. Trans Neurosci Clin, 2016, 2(2):138-149.

[1]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[2]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[3]	JIANG Daoli, CHOU Xiaohua, LIU Zhidong, LI Wei, ZHANG Bo, XU Sang, TAN Defei, FANG Yi, LV Dongmei, WANG Tao. Real-world study of ceftazidime-avibactam in the treatment of multidrug-resistant gram-negative bacterial infections [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1008-1017.
[4]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[5]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[6]	WANG Jingang, LI Qiang, SUN Huiyan, WANG Hongquan. Recent progress in understanding the neuroprotective mechanism of carnosic acid in Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1073-1080.
[7]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[8]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[9]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[10]	LI Mengxi, ZHANG Kejing, XIA Fan. Research progress in vaccine for breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 918-925.
[11]	CHEN Qun, ZHU Heping, YUAN Xiaolong. Analysis of 197 cases of pentoxifylline injection and exploring supervision mode of rational drug use in hospitals [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 948-953.
[12]	ZHANG Taotao, SU Wenxiu, TIAN Limin. Research progress on the relationship between subclinical hypothyroidism and depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 954-960.
[13]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[14]	XU Xiuhe, HE Xiaoli, ZHOU Jiashun, PAN Lizhu, ZHOU Zhuojun, LI Jiayue, WANG Caixia, YUAN Wei, ZHU Guiqi. Effects of scacia honey on serum uric acid level and renal injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 743-750.
[15]	WANG Xinyu, CHEN Yipeng, MA Yongli, HE Junfei. Study of the improvement effect of "DuZhong-DangGui" on osteoarthritis rats via regulating NLPR3 inflammasome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 751-757.